With the FDA having granted full traditional approval to the anti-amyloid Alzheimer’s disease (AD) drug lecanemab-irmb (Leqembi, Eisai) on July 6, and the Centers for Medicare & Medicaid Services (CMS) confirming that it will cover 80% of the medication’s cost without requiring participation in a randomized clinical trial, the landscape of AD treatment in the United States is about to look very different.
“It’s been a transformative year for the treatment